ArticlesThe Monoethylglycinexylidide Test Does Not Impair Psychometric Performance in Patients With Chronic Hepatitis or CirrhosisBotta, Federica* ; Giannini, Edoardo* ; Fasoli, Alberto* ; Romagnoli, Paola* ; Risso, Domenico†; Testa, Roberto*Author Information *Gastroenterology Unit, Department of Internal Medicine, University of Genoa; †Institute of Medical Statistics and Biometry, University of Genoa, Genoa, Italy Received July 21, 1999; accepted December 27, 1999. Address correspondence and reprint requests to Prof. Roberto Testa, Gastroenterology Unit, Department of Internal Medicine, Viale Benedetto XV no6, 16132 Genova, Italy Therapeutic Drug Monitoring: August 2000 - Volume 22 - Issue 4 - p 371-374 Buy Abstract Lidocaine (LID) is an aminoethylamide used in hepatology to perform the monoethylglycinexylidide (MEGX) test for the evaluation of liver function in patients with cirrhosis (CIR) or chronic hepatitis (CH). The authors evaluated whether the MEGX test changes psychometric performance in patients with chronic liver disease and, in particular, whether it might trigger subclinical portosystemic encephalopathy in patients with CIR. Thirty patients with CIR and 20 patients with CH were studied. They underwent a standard-dose MEGX test, before and after which a psychometric test was administered and blood pressure, heart rate, and adverse effects were recorded. The MEGX test did not modify psychometric performance. Mean arterial blood pressure and heart rate did not change at the end of the MEGX test in either patients with CH or CIR. Adverse effects were present in 66% of all patients during lidocaine injection and lasted up to 3 minutes afterwards. They were more frequent in patients with CH than in patients with CIR (85% vs 53%). No relationship was found between adverse effects and lidocaine dosage, nor between adverse effects and MEGX or lidocaine concentration at 15 minutes. Standard-dose MEGX test does not worsen or trigger portosystemic encephalopathy in CIR. Adverse effects were frequent but mild. © 2000 Lippincott Williams & Wilkins, Inc.